COLL vs KIM · P/E 17, rev $181.9M vs P/E 27, $16.03B cap
Collegium Pharmaceutical Inc (COLL) versus Kimco Realty Corporation (KIM) — a side-by-side from cached financials, not a winner call.
Collegium Pharmaceutical Inc (COLL) is a drug manufacturers - specialty & generic company listed on NASDAQ.
Kimco Realty Corporation (KIM) is a reit - retail company listed on US.
Latest reported COLL revenue for 2024-12-31 was $181.9M. Net income was $69.2M. Revenue was up 14.2% from 2024-09-30 to 2024-12-31. COLL currently screens at market cap $1.12B and trailing P/E 16.8.
KIM does not have a complete income-statement cache yet.
COLL currently screens at market cap $1.12B and trailing P/E 16.8. KIM currently screens at market cap $16.03B and trailing P/E 27.3.
Not investment advice. Open the COLL and KIM stock pages for the full models.
Not investment advice.